Early non-clinical and initial human data from studies involving patients with multiple myeloma have shown mezagitamab to have a favorable safety profile and promising pharmacodynamic effects, particularly in the reduction of CD38-expressing target cells [186, 187]. The gene discussed is CD38; the disease is plasma cell myeloma.